keyword
MENU ▼
Read by QxMD icon Read
search

ingenol mebutate

keyword
https://www.readbyqxmd.com/read/27904293/superficial-basal-cell-carcinoma-treated-with-two-cycles-of-ingenol-mebutate-gel-0-015
#1
Yu Seok Jung, Ji Hae Lee, Jung Min Bae, Gyong Moon Kim
No abstract text is available yet for this article.
December 2016: Annals of Dermatology
https://www.readbyqxmd.com/read/27860083/dermoscopic-monitoring-of-efficacy-of-ingenol-mebutate-in-the-treatment-of-pigmented-and-non-pigmented-basal-cell-carcinomas
#2
Laura Diluvio, Mauro Bavetta, Monia Di Prete, Augusto Orlandi, Luca Bianchi, Elena Campione
Basal cell carcinoma is the most common non-melanoma skin cancer, and its incidence continues to raise. Although surgery can be considered the mainstay of therapy, new current pharmacological options are available and focus on tumor eradication, maximizing cosmetic results, and functional capacity. Several studies have recently reported on safety and efficacy of topical ingenol mebutate gel, a derivative of the plant Euphorbia Peplus, used to treat actinic keratosis and superficial basal cell carcinoma. In our knowledge, we report for the first time the dermoscopic evaluation of outcome and monitoring of superficial pigmented and non-pigmented basal cell carcinomas in four patients treated by this novel non-ablative agent...
November 12, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27859830/fast-evaluation-and-monitoring-of-ingenol-mebutate-treatment-of-multiple-basal-cell-carcinomas-by-in-vivo-hand-held-reflectance-confocal-microscopy
#3
E Manubens, A Barreiro, A Bennassar, S Podlipnik, N Moreno, P Iglesias, J Malvehy, S Puig
Patients presenting multiple basal cell carcinomas (BCCs) are increasing and their management often entails a challenge for dermatologists(1) . In vivo reflectance confocal microscopy (RCM) has demonstrated in a recent metanalysis a very good performance in the diagnosis of BCC, opening a new alternative in the evaluation of these patients(2) . An 82 year old man with history of approximately 30 BCC over the last 30 years was referred to our clinic. This article is protected by copyright. All rights reserved...
November 11, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27853385/efficacy-of-ingenol-mebutate-gel-for-actinic-keratosis-in-patients-treated-by-thiazide-diuretics
#4
Elena Campione, Monia Di Prete, Laura Diluvio, Luca Bianchi, Augusto Orlandi
Actinic keratosis (AK) is considered as superficial squamous cell carcinoma. Chronic sun exposure plays a central role in its pathogenesis. In particular, ultraviolet B radiation causes direct damage to the DNA, producing pyrimidine dimers that suppress the protective role of p53. Other risk factors include advanced age, male sex, and fair skin type. Even some drugs used for treating blood hypertension, such as thiazide diuretics, can increase the risk of developing AK. Their photosensitizing action seems to be connected with reactive oxygen species production...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27785771/pharmacoeconomic-considerations-in-treating-actinic-keratosis-an-update
#5
REVIEW
Spencer M Vale, Dane Hill, Steven R Feldman
Actinic keratosis is one of the most common dermatological diagnoses worldwide, especially among the elderly, fair-skinned, and immunocompromised, and is associated with a risk of transformation to skin cancer. With actinic keratosis and skin cancer prevalence increasing as the aged population expands in the US, optimizing treatment strategies may produce cost savings for the healthcare system. Since the time of our last review in 2008, investigation of the economic considerations in treating actinic keratosis has advanced...
October 27, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27784514/survey-of-patient-satisfaction-with-ingenol-mebutate-gel-treatment-for-actinic-keratosis-from-a-community-dermatology-practice
#6
Dale Schaefer
Actinic keratosis (AK) is a condition that can present as a discrete lesion or as areas of confluent lesions. It is generally treated either with cryosurgery or, less frequently, with patient-applied topical medications or photodynamic therapy. Topical therapies can offer benefits over cryosurgery, especially in patients with significant actinic damage. The long durations of topical treatment required and the persistence of associated local skin reactions (LSRs) may deter some patients from adhering to topical therapies and thus affect clinical outcomes...
2016: Skinmed
https://www.readbyqxmd.com/read/27741334/biological-effects-of-ingenol-mebutate-gel-in-moderate-to-severe-actinic-fields-assessed-by-reflectance-confocal-microscopy-a-phase-i-study
#7
Martina Ulrich, Susanne Lange-Asschenfeldt, Kresten Skak, Torsten Skov, Marie Louise Østerdal, Hans-Joachim Röwert-Huber, John Robert Zibert, Eggert Stockfleth
Ingenol mebutate represents a topical treatment for fields with actinic keratosis (AK). The biological effects of ingenol mebutate in AK, subclinical (SC)-AK, and reference-skin were assessed and graded by in vivo reflectance confocal microscopy (RCM) and histology. Patients with AK and SC-AK lesions in one 25 cm2 field on hands or forearms, and with an area of reference skin on the inner upper arm, were included. The two fields were each treated with ingenol mebutate 0.05% gel (n=16), or vehicle (n=8), on 2 consecutive days; clinical and RCM assessments were performed on days 1, 2, 3, 8, and 57, and biopsies on day 3...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27730685/lesion-intensified-field-therapy-lift-a-new-concept-in-the-treatment-of-actinic-field-cancerization
#8
S A Braun, P A Gerber
actinic field cancerization (AFC) is a frequent neoplastic skin disease with a high prevalence in the elderly population. AFC is defined as a condition with at least six actinic keratosis (AKs) in one body region or field of chronically sun-damaged skin.(1) With regard to the management of AFC a superior efficacy has been demonstrated for field-directed treatments, such as 5-fluorouracil, imiquimod, ingenol mebutate or photodynamic therapy (PDT), as compared to lesion-directed measures, such as cryotherapy...
October 12, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27672408/an-investigator-initiated-study-to-assess-the-safety-and-efficacy-of-ingenol-mebutate-0-05-gel-when-used-after-cryosurgery-in-the-treatment-of-hypertrophic-actinic-keratosis-on-dorsal-hands
#9
Peter W Hashim, John K Nia, Skylar Singer, Gary Goldenberg
OBJECTIVES: To evaluate the safety and efficacy of ingenol mebutate 0.05% gel after cryosurgery versus cryosurgery alone for the treatment of hypertrophic and nonhypertrophic actinic keratosis on the dorsal hands. DESIGN: Investigator-blinded split arm study. SETTING: Academic institution. PARTICIPANTS: Sixteen subjects with actinic keratoses on dorsal hands. RESULTS: There was a mean reduction in the number of hypertrophic actinic keratosis lesions adjusted for baseline in ingenol mebutate-treated versus control group of -4...
July 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/27636884/repeated-treatments-with-ingenol-mebutate-prevents-progression-of-uv-induced-photodamage-in-hairless-mice
#10
Andrés Már Erlendsson, Daniel Thaysen-Petersen, Christiane Bay, Andreas Hald, Kresten Skak, John Robert Zibert, Uwe Paasch, Hans Christian Wulf, Merete Haedersdal
BACKGROUND AND AIM: Ingenol mebutate (IngMeb) is an effective treatment for actinic keratosis. In this study, we hypothesized that repeated treatments with IngMeb may prevent progression of UV-induced photodamage, and that concurrent application of a corticosteroid may reduce IngMeb-induced local skin responses (LSR). METHODS: Hairless mice (n = 60; 3 groups of 20 mice) were irradiated with solar simulated ultraviolet radiation (UVR) throughout the study. Five single treatments with IngMeb were given at 4-week intervals (Days 21, 49, 77, 105, and 133)...
2016: PloS One
https://www.readbyqxmd.com/read/27612149/tumor-preferential-induction-of-immune-responses-and-epidermal-cell-death-in-actinic-keratoses-by-ingenol-mebutate
#11
Steffen Emmert, Holger A Haenssle, John R Zibert, Margarete Schön, Andreas Hald, Maria H Hansen, Thomas Litman, Michael P Schön
UNLABELLED: The rapid and strong clinical efficacy of the first-in-class, ingenol mebutate, against actinic keratosis (AK) has resulted in its recent approval. We conducted the first comprehensive analysis of the cellular and molecular mode of action of topical ingenol mebutate 0.05% gel in both AK and uninvolved skin of 26 patients in a phase I, single-center, open-label, within-patient comparison. As early as 1 day after application, ingenol mebutate induced profound epidermal cell death, along with a strong infiltrate of CD4+ and CD8+ T-cells, neutrophils, and macrophages...
2016: PloS One
https://www.readbyqxmd.com/read/27601928/relationship-between-severity-of-the-local-skin-reactions-and-the-rate-of-local-skin-reaction-resolution-in-patients-treated-with-ingenol-mebutate-gel
#12
Shelbi C Jim On, Kim Mark Knudsen, Torsten Skov, Mark Lebwohl
BACKGROUND: Ingenol mebutate gel is a topical field treatment for actinic keratosis (AK). The treatment elicits application-site reactions in most patients. This analysis evaluated the relationship between the severity of reactions and the speed of their resolution. METHODS: Patients in Phase III studies were treated for AKs on the face (n=218), scalp (n=56), and trunk and extremities (n=209). All of the patients were treated with either ingenol mebutate gel 0.015% once daily for three consecutive days (face/scalp) or ingenol mebutate gel 0...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27578305/a-randomized-split-face-clinical-trial-of-photodynamic-therapy-with-methyl-aminolevulinate-versus-ingenol-mebutate-gel-for-the-treatment-of-multiple-actinic-keratoses-of-the-face-and-scalp
#13
Cristina Zane, Antonella Fabiano, Mariachiara Arisi, Piergiacomo Calzavara-Pinton
BACKGROUND: Photodynamic therapy with methyl aminolevulinate (MAL-PDT) and ingenol mebutate gel (IMB) are approved therapeutic options for multiple actinic keratoses (AKs). OBJECTIVE: The aim of this intraindividual, split-face, randomized clinical trial was to compare treatment outcomes of MAL-PDT and IMB. METHODS: Two symmetrical contralateral areas with a similar number of AKs were selected and randomly assigned to 3 days of an IMB treatment cycle or a single session of MAL-PDT...
2016: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/27574458/treatment-of-superficial-basal-cell-carcinoma-with-ingenol-mebutate-gel-0-05
#14
Miriam S Bettencourt
BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in Caucasians. Surgical approaches are the most widely used and effective treatment strategies for well-defined BCC. However, for patients with low-risk, superficial BCCs (sBCCs), medical therapy may be a treatment option. In this small case series, we describe our experience in using topical treatment with ingenol mebutate gel, 0.05%, for patients who refused surgical treatment for sBCC. METHODS: We conducted a retrospective chart review of seven patients from our community dermatology practice for whom sBCC was treated with ingenol mebutate...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27567085/repeated-treatments-with-ingenol-mebutate-for-prophylaxis-of-uv-induced-squamous-cell-carcinoma-in-hairless-mice
#15
Andrés M Erlendsson, Daniel Thaysen-Petersen, Christiane Bay, Catharina M Lerche, Peter A Philipsen, Hans Christian Wulf, John R Zibert, Merete Hædersdal
BACKGROUND AND AIM: The incidence of squamous cell carcinomas (SCC) is increasing, and effective chemopreventative strategies are needed. We hypothesized that repeated treatments with ingenol mebutate (IngMeb) would postpone development of SCC in hairless mice, and that application of a corticosteroid would reduce IngMeb-induced local skin responses (LSRs) without affecting tumor postponement. METHODS: Hairless mice (n=150; 6 groups á 25 mice) were irradiated with solar simulated ultraviolet radiation (UVR) until SCC developed...
October 2016: Journal of Photochemistry and Photobiology. B, Biology
https://www.readbyqxmd.com/read/27550505/successfully-treated-superficial-basal-cell-carcinomas-with-ingenol-mebutate-0-05-gel-report-of-twenty-cases
#16
S Izzi, P Sorgi, P Piemonte, A Carbone, P Frascione
Surgery is the therapy of choice in the guidelines to treat basal cell carcinomas (BCCs) but a variety of non-surgical options are available. The objective of this study is to evaluate the efficacy and safety of ingenol mebutate 0.05% gel for the treatment of superficial BCCs. We accepted twenty patients with superficial BCCs on the body and we treated them once daily for two consecutive days with ingenol mebutate 0.05% gel. We examined the lesions at the screening visit and after four days from the gel application to describe the local skin reaction due to the therapy...
August 23, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27548156/synthesis-and-cytotoxicity-against-k562-cells-of-3-o-angeloyl-20-o-acetyl-ingenol-a-derivative-of-ingenol-mebutate
#17
Ming Liu, Fangling Chen, Rilei Yu, Weiyi Zhang, Mei Han, Fei Liu, Jing Wu, Xingzeng Zhao, Jinlai Miao
Ingenol mebutate possesses significant cytotoxicity and is clinically used to treat actinic keratosis. However, ingenol mebutate undergoes acyl migration which affects its bioactivity. Compound 3-O-angeloyl-20-O-acetyl ingenol (AAI, also known as 20-O-acetyl-ingenol-3-angelate or PEP008) is a synthetic derivative of ingenol mebutate. In this work, we report the AAI synthesis details and demonstrate AAI has higher cytotoxicity than ingenol mebutate in a chronic myeloid leukemia K562 cell line. Our data indicate that the increased activity of AAI originates from the improved intracellular stability of AAI rather than the increased binding affinity between AAI and the target protein protein kinase Cδ (PKCδ)...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27530375/a-randomized-split-face-clinical-trial-of-daylight-photodynamic-therapy-with-methyl-aminolaevulinate-vs-ingenol-mebutate-gel-for-the-treatment-of-multiple-actinic-keratoses-of-the-face-and-scalp
#18
Erica Moggio, Mariachiara Arisi, PierGiacomo Calzavara-Pinton
INTRODUCTION: Daylight photodynamic therapy with methyl aminolaevulinate (dlPDT) and ingenol mebutate gel (IMB) are approved therapeutic options for multiple actinic keratoses (AKs). The aim of this comparative, intra-patient, split- face, randomized clinical trial was to compare treatment outcomes of dlPDT and IMB. METHODS: Two symmetrical contralateral areas of 25cm(2) harboring a similar (≥5) number of AKs were selected and randomly assigned to 3 days' IMB treatment cycle or an only session of dlPDT...
August 13, 2016: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/27518593/histological-examination-confirms-clinical-clearance-of-aks-following-treatment-with-ingenol-mebutate-0-05-gel
#19
M Ulrich, U Reinhold, T Skov, R Elvang Søndergaard, P Guitera
BACKGROUND: To date, studies with ingenol mebutate gel have used clinical clearance, not histological clearance, as a primary efficacy endpoint. OBJECTIVES: This phase 1, multicentre, single-arm, open-label study sought to histologically confirm clinical clearance of actinic keratoses (AKs) to support a treatment effect deep in the epidermis. METHODS: Patients (n = 108) aged ≥18 years with histologically confirmed AK within a 25-cm(2) contiguous treatment area on the trunk and extremities received ingenol mebutate 0...
August 12, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27513957/bowenoid-actinic-keratosis-and-bowen-s-disease-treated-successfully-with-ingenol-mebutate
#20
Mosab T Mohanna, Günther F L Hofbauer
Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis (AK). We report 2 cases with off-label use of IM. The first case of bowenoid AK was treated with 150 μg IM for 3 consecutive days with an almost complete clinical remission of the lesion. The second case of Bowen's disease was treated with 500 μg IM for 2 consecutive days leading to complete clinical remission.
2016: Dermatology: International Journal for Clinical and Investigative Dermatology
keyword
keyword
51369
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"